BE2022C531I2 - - Google Patents

Download PDF

Info

Publication number: BE2022C531I2
Authority: BE; Belgium

Application number

BE2022C531C

Other languages

Dutch (nl)

Original Assignee

Janssen Pharmaceutica Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-08-13

Filing date

2022-07-28

Publication date

2022-08-09

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26076978&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2022C531(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2022-07-28 Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv

2022-08-09 Publication of BE2022C531I2 publication Critical patent/BE2022C531I2/nl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
- C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
- C07C255/42—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
- C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
- C07C257/12—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to hydrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Virology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Molecular Biology (AREA)
AIDS & HIV (AREA)
Bioinformatics & Cheminformatics (AREA)
Tropical Medicine & Parasitology (AREA)
Engineering & Computer Science (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

BE2022C531C 2001-08-13 2022-07-28 BE2022C531I2 (da)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
EP01203090		2001-08-13
EP02077748		2002-06-10
EP02764839A EP1419152B1 (en)	2001-08-13	2002-08-09	Hiv inhibiting pyrimidines derivatives
PCT/EP2002/008953 WO2003016306A1 (en)	2001-08-13	2002-08-09	Hiv inhibiting pyrimidines derivatives
EP10178189.6A EP2298761B1 (en)	2001-08-13	2002-08-09	Hiv inhibiting pyrimidines derivatives

Publications (1)

Publication Number	Publication Date
BE2022C531I2 true BE2022C531I2 (da)	2022-08-09

Family

ID=26076978

Family Applications (3)

Application Number	Title	Priority Date
BE2012C020C BE2012C020I2 (da)	2001-08-13	2012-05-08
BE2012C022C BE2012C022I2 (da)	2001-08-13	2012-05-24
BE2022C531C BE2022C531I2 (da)	2001-08-13	2022-07-28

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
BE2012C020C BE2012C020I2 (da)	2001-08-13	2012-05-08
BE2012C022C BE2012C022I2 (da)	2001-08-13	2012-05-24

Country Status (38)

Country	Link
US (8)	US7125879B2 (da)
EP (3)	EP3808743B1 (da)
JP (4)	JP2005507380A (da)
KR (2)	KR100817453B1 (da)
CN (2)	CN100509801C (da)
AP (1)	AP1610A (da)
AR (1)	AR036387A1 (da)
AT (1)	ATE517891T1 (da)
AU (1)	AU2002329238C1 (da)
BE (3)	BE2012C020I2 (da)
BR (3)	BR122015023612B8 (da)
CA (1)	CA2452217C (da)
CY (4)	CY1112331T1 (da)
DE (1)	DE122012000038I1 (da)
DK (2)	DK1419152T3 (da)
EA (1)	EA006656B1 (da)
EG (1)	EG24684A (da)
ES (3)	ES2799408T3 (da)
FR (3)	FR12C0035I2 (da)
HK (2)	HK1070066A1 (da)
HR (3)	HRP20192051B1 (da)
HU (5)	HU231274B1 (da)
IL (2)	IL160328A0 (da)
JO (1)	JO3429B1 (da)
LT (2)	LT3808743T (da)
LU (2)	LU92001I2 (da)
MX (1)	MXPA04001401A (da)
MY (1)	MY189572A (da)
NO (3)	NO327639B1 (da)
NZ (1)	NZ530951A (da)
OA (1)	OA12652A (da)
PA (1)	PA8552901A1 (da)
PL (2)	PL216398B1 (da)
PT (1)	PT1419152E (da)
SI (2)	SI1419152T1 (da)
UA (1)	UA78221C2 (da)
WO (1)	WO2003016306A1 (da)
ZA (1)	ZA200401159B (da)

Families Citing this family (152)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JO3429B1 (ar)	2001-08-13	2019-10-20	Janssen Pharmaceutica Nv	مشتقات برميدينات مثبطة فيروس الايدز
MY169670A (en) *	2003-09-03	2019-05-08	Tibotec Pharm Ltd	Combinations of a pyrimidine containing nnrti with rt inhibitors
US7638522B2 (en) *	2001-08-13	2009-12-29	Janssen Pharmaceutica N.V.	Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
US8101629B2 (en) *	2001-08-13	2012-01-24	Janssen Pharmaceutica N.V.	Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
TWI329105B (en)	2002-02-01	2010-08-21	Rigel Pharmaceuticals Inc	2,4-pyrimidinediamine compounds and their uses
JP4836405B2 (ja)	2002-03-13	2011-12-14	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	ヒストンデアセチラーゼの新規な阻害剤としてのアミノカルボニル誘導体
AR039540A1 (es) *	2002-05-13	2005-02-23	Tibotec Pharm Ltd	Compuestos microbicidas con contenido de pirimidina o triazina
JP2006514989A (ja)	2002-07-29	2006-05-18	ライジェルファーマシューティカルズ	２，４−ピリミジンジアミン化合物による自己免疫疾患の治療および予防方法
CA2493794C (en) *	2002-08-09	2010-05-25	Janssen Pharmaceutica N.V.	Processes for the preparation of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
US7504410B2 (en) *	2002-11-28	2009-03-17	Schering Aktiengesellschaft	Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents
CL2004000192A1 (es) *	2003-02-07	2005-03-18	Janssen Pharmaceutica Nv	Uso de compuestos derivados de 2-aminopirimidina para preparar un medicamento para la prevencion de una infeccion por vih relaciones sexuales o un contacto intimo en la pareja.
DE602004015254D1 (de) *	2003-02-07	2008-09-04	Janssen Pharmaceutica Nv	Hiv-inhibierende1,2,4-triazine
CL2004000303A1 (es)	2003-02-20	2005-04-08	Tibotec Pharm Ltd	Compuestos derivados de pirimidinas y triazinas; proceso de preparacion; composicion farmaceutica; y su uso para inhibir la replicacion del vih.
ES2667668T3 (es)	2003-07-17	2018-05-14	Janssen Sciences Ireland Uc	Procedimiento para preparar partículas que contienen un antiviral
US7122542B2 (en)	2003-07-30	2006-10-17	Rigel Pharmaceuticals, Inc.	Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
DK2287156T3 (da) *	2003-08-15	2013-08-26	Novartis Ag	2,4-Di(phenylamino)-pyrimidiner egnede i behandling af neoplastiske sygdomme, inflammatoriske lidelser og lidelser i immunsystemet
TWI365744B (en) *	2003-09-03	2012-06-11	Tibotec Pharm Ltd	Combinations of a pyrimidine containing nnrti with rt inhibitors
CN100475815C (zh) *	2003-09-25	2009-04-08	詹森药业有限公司	抑制hiv复制的嘌呤衍生物
RU2006139258A (ru)	2004-04-08	2008-05-20	Таргеджен, Инк. (US)	Бензотриазиновые ингибиторы киназ
CA2572833C (en)	2004-07-28	2013-04-09	Janssen Pharmaceutica N.V.	Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase
JP5031564B2 (ja)	2004-08-10	2012-09-19	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	Ｈｉｖ抑制１，２，４−トリアジン−６−オン誘導体
SG155246A1 (en)	2004-08-25	2009-09-30	Ardea Biosciences Inc	S-TRIAZOLYL α-MERCAPTOACETANILIDES AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE
WO2007050087A1 (en)	2004-08-25	2007-05-03	Ardea Biosciences, Inc.	N[S(4-aryl-triazol-3-yl)α -mercaptoacetyl]-p-amino benozoic acids AS HIV REVERSE TRANSCRIPTASE INHIBITORS
UA92469C2 (en) *	2004-09-02	2010-11-10	Янссен Фармацевтика Н.В.	Fumarate of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl amino benzonitrile
AU2005279158C1 (en) *	2004-09-02	2010-12-16	Janssen Pharmaceutica N.V.	Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl] amino]benzonitrile
ATE508748T1 (de) *	2004-09-02	2011-05-15	Janssen Pharmaceutica Nv	Salz von 4-ää4-ää4-(2-cyanoethenyl)-2,6- dimethylphenylüaminoü-2- pyrimidinylüaminoübenzonitril.
AU2005279157B2 (en) *	2004-09-02	2011-07-14	Janssen Pharmaceutica N.V.	Fumarate of 4-[[4-[[4- (2-cyanoethenyl) -2,6-dimethylphenyl]amino)-2-pyrimidinyl)amino]benzonitrile
SI1789139T1 (sl) *	2004-09-02	2012-08-31	Janssen Pharmaceutica Nv	Fumarat 4-((4-((4-(2-cianoetenil)-2,6-dimetifenil amino-2-pirimidinil amino benzonitrila
EP2316458A1 (en)	2004-09-20	2011-05-04	Xenon Pharmaceuticals Inc.	Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase
CA2580844A1 (en)	2004-09-20	2006-03-30	Xenon Pharmaceuticals Inc.	Heterocyclic derivatives and their use as mediators of stearoyl-coa desaturase
EP1799664A1 (en)	2004-09-20	2007-06-27	Xenon Pharmaceuticals Inc.	Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
CA2580855A1 (en)	2004-09-20	2006-03-30	Xenon Pharmaceuticals Inc.	Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
BRPI0515483A (pt)	2004-09-20	2008-07-22	Xenon Pharmaceuticals Inc	derivados heterocìclicos para o tratamento de doenças mediadas por enzimas estearoil-coa desaturase
AU2005329423A1 (en)	2004-09-20	2006-09-28	Xenon Pharmaceuticals Inc.	Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
JP5043668B2 (ja)	2004-09-20	2012-10-10	ゼノン・ファーマシューティカルズ・インコーポレイテッド	複素環誘導体および治療薬としてのそれらの使用
ATE542802T1 (de)	2004-09-30	2012-02-15	Tibotec Pharm Ltd	Hiv-inhibierende 5-substituierte pyrimidine
EP1797048B1 (en) *	2004-09-30	2011-08-17	Tibotec Pharmaceuticals	Hiv inhibiting 5-carbo- or heterocyclic substituted pyrimidines
JP5008567B2 (ja)	2004-09-30	2012-08-22	テイボテク・フアーマシユーチカルズ	Ｈｉｖ阻害性５−ヘテロシクリルピリミジン
CA2584295C (en)	2004-11-24	2014-08-26	Rigel Pharmaceuticals, Inc.	Spiro-2, 4-pyrimidinediamine compounds and their uses
SI1856135T1 (sl)	2005-01-19	2010-04-30	Rigel Pharmaceuticals Inc	Predzdravila 2,4-pirimidindiaminskih spojin in njihove uporabe
ES2548729T3 (es)	2005-03-31	2015-10-20	Santen Pharmaceutical Co., Ltd.	Nuevo compuesto cíclico que tiene grupo pirimidinilalquiltio
TW201414495A (zh) *	2005-04-04	2014-04-16	Tibotec Pharm Ltd	Ｈｉｖ-感染之預防
BRPI0611455A2 (pt)	2005-05-05	2010-09-08	Ardea Biosciences Inc	diaril-purinas, azapurinas e deazapurinas como inibidores não nucleosìdicos da transcriptase reversa para tratamento de hiv
CN101248051B (zh) *	2005-05-26	2013-07-17	泰博特克药品有限公司	制备4-[(1,6-二氢-6-氧代-2-嘧啶基)氨基]苯基氰的方法
WO2007130075A1 (en)	2005-06-03	2007-11-15	Xenon Pharmaceuticals Inc.	Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
US20070203161A1 (en)	2006-02-24	2007-08-30	Rigel Pharmaceuticals, Inc.	Compositions and methods for inhibition of the jak pathway
CN105348203B (zh)	2005-06-08	2018-09-18	里格尔药品股份有限公司	抑制jak途径的组合物和方法
RU2589878C2 (ru)	2005-11-01	2016-07-10	Таргеджен, Инк.	Би-арил-мета-пиримидиновые ингибиторы киназ
CN101370790B (zh)	2006-01-19	2015-10-21	詹森药业有限公司	作为组蛋白去乙酰化酶抑制剂的吡啶和嘧啶衍生物
CN101370504A (zh)	2006-01-20	2009-02-18	泰博特克药品有限公司	用tcm278对hiv感染进行的长期治疗
US8933089B2 (en)	2006-03-30	2015-01-13	Janssen R & D Ireland	HIV inhibiting 5-amido substituted pyrimidines
DK2004641T3 (da)	2006-03-30	2011-01-24	Tibotec Pharm Ltd	HIV-inhiberende 5-(hydroxymethylen og aminomethylen) substituerede pyrimidiner
CA2654115C (en) *	2006-06-23	2015-12-22	Tibotec Pharmaceuticals Ltd.	Aqueous suspensions of tmc278
AU2016219555B2 (en) *	2006-06-23	2017-08-10	Janssen Sciences Ireland Uc	Aqueous suspensions of TMC278
AU2014200819B2 (en) *	2006-06-23	2016-05-26	Janssen Sciences Ireland Uc	Aqueous suspensions of TMC278
CA2668997C (en)	2006-11-09	2012-10-09	Ardea Biosciences, Inc.	4-cyanophenylamino-substituted bicyclic heterocyclic compounds as hiv inhibitors
RS53588B1 (en)	2006-12-08	2015-02-27	Irm Llc	COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS
AU2007332654B2 (en) *	2006-12-13	2013-06-20	F. Hoffmann-La Roche Ag	2-(piperidin-4-yl)-4-phenoxy- or phenylamino-pyrimidine derivatives as non-nucleoside reverse transcriptase inhibitors
EP2114902B1 (en)	2006-12-29	2014-09-17	Janssen R&D Ireland	Hiv inhibiting 5,6-substituted pyrimidines
EP2114901B1 (en)	2006-12-29	2014-04-09	Janssen R&D Ireland	Hiv inhibiting 6-substituted pyrimidines
EP2121613A2 (en)	2007-01-31	2009-11-25	Vertex Pharmaceuticals, Inc.	2-aminopyridine derivatives useful as kinase inhibitors
CL2008000746A1 (es) *	2007-03-14	2008-09-22	Tibotec Pharm Ltd	Composicion farmaceutica en solucion que comprende tmc278 y un polimero soluble en agua; proceso de preparacion de dicha composicion; y uso de un polvo que comprende tmc278 para tratar sida.
AP2009005010A0 (en)	2007-04-18	2009-10-31	Pfizer Prod Inc	Sulfonyl amide derivatives for the treatment of abnormal cell growth
MX2009012704A (es)	2007-05-30	2009-12-08	Hoffmann La Roche	Inhibidores de transcriptasa inversa de no nucleosidos.
KR101294731B1 (ko) *	2007-06-04	2013-08-16	삼성디스플레이 주식회사	어레이 기판, 이를 갖는 표시패널 및 이의 제조방법
RU2498979C2 (ru) *	2007-07-12	2013-11-20	Тиботек Фармасьютикалз	Кристаллическая форма 4-[[4-[[4-(2-цианоэтенил)-2,6-диметилфенил]амино]-2-пиримидинил]амино]бензонитрила
CN101407476B (zh) *	2007-10-12	2012-07-18	中国人民解放军军事医学科学院毒物药物研究所	作为非核苷类hiv逆转录酶抑制剂的间二芳烃-多取代苯胺类化合物、其制备方法及用途
ES2513390T3 (es)	2007-11-27	2014-10-27	Ardea Biosciences, Inc.	Nuevos compuestos y composiciones, y métodos de uso
CA2709176C (en)	2007-12-14	2013-02-05	Ardea Biosciences, Inc.	Reverse transcriptase inhibitors
US11351168B1 (en)	2008-06-27	2022-06-07	Celgene Car Llc	2,4-disubstituted pyrimidines useful as kinase inhibitors
US8338439B2 (en)	2008-06-27	2012-12-25	Celgene Avilomics Research, Inc.	2,4-disubstituted pyrimidines useful as kinase inhibitors
KR20110025224A (ko)	2008-06-27	2011-03-09	아빌라 테라퓨틱스, 인크.	헤테로아릴 화합물 및 이의 용도
US8569337B2 (en)	2008-07-23	2013-10-29	Vertex Pharmaceuticals Incorporated	Tri-cyclic pyrazolopyridine kinase inhibitors
WO2010011756A1 (en)	2008-07-23	2010-01-28	Vertex Pharmaceuticals Incorporated	Pyrazolopyridine kinase inhibitors
CA2731498A1 (en)	2008-07-23	2010-01-28	Vertex Pharmaceuticals Incorporated	Tri-cyclic pyrazolopyridine kinase inhibitors
MX2011001319A (es) *	2008-08-06	2011-04-05	Vertex Pharma	Inhibidores de aminopiridina cinasa.
US8933106B2 (en)	2008-10-09	2015-01-13	Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. China	2-(4-substituted phenylamino) polysubstituted pyridine compounds as inhibitors of non-nucleoside HIV reverse transcriptase, preparation methods and uses thereof
CN101717364B (zh) *	2008-10-09	2014-08-13	中国人民解放军军事医学科学院毒物药物研究所	作为hiv逆转录酶抑制剂的吡啶类化合物及其制备方法和用途
EP2181991A1 (en)	2008-10-28	2010-05-05	LEK Pharmaceuticals D.D.	Novel salts of sunitinib
EP2186809A1 (en) *	2008-11-13	2010-05-19	LEK Pharmaceuticals D.D.	New crystal form of sunitinib malate
MY160360A (en)	2008-12-24	2017-02-28	Janssen Sciences Ireland Uc	Implantable devices for treating hiv
ES2659725T3 (es)	2009-05-05	2018-03-19	Dana-Farber Cancer Institute, Inc.	Inhibidores de EGFR y procedimiento de tratamiento de trastornos
EP2427464A1 (en)	2009-05-06	2012-03-14	Vertex Pharmaceuticals Incorporated	Pyrazolopyridines
RS57728B1 (sr)	2010-01-27	2018-12-31	Viiv Healthcare Co	Antivirusna terapija
WO2011094273A1 (en)	2010-01-27	2011-08-04	Vertex Pharmaceuticals Incorporated	Pyrazolopyridine kinase inhibitors
JP2013518113A (ja)	2010-01-27	2013-05-20	バーテックスファーマシューティカルズインコーポレイテッド	ピラゾロピラジンキナーゼ阻害剤
EP2582702A1 (en)	2010-01-27	2013-04-24	Vertex Pharmaceuticals Incorporated	Pyrazolopyrimidine kinase inhibitors
US20140018379A1 (en) *	2010-02-18	2014-01-16	Concert Pharmaceuticals Inc.	Pyrimidine derivatives
US8367315B2 (en)	2010-03-05	2013-02-05	Adan Rios	Inactivation of reverse transcriptases by azido-diarylpyrimidines
EP2603081B1 (en)	2010-08-10	2016-10-05	Celgene Avilomics Research, Inc.	Besylate salt of a btk inhibitor
US9238629B2 (en)	2010-11-01	2016-01-19	Celgene Avilomics Research, Inc.	Heteroaryl compounds and uses thereof
PH12013500870A1 (en)	2010-11-01	2013-06-03	Celgene Car Llc	Heterocyclic compounds and uses thereof
WO2012060847A1 (en)	2010-11-07	2012-05-10	Targegen, Inc.	Compositions and methods for treating myelofibrosis
ES2665013T3 (es)	2010-11-10	2018-04-24	Celgene Car Llc	Inhibidores de EGFR selectivos de mutante y usos de los mismos
PT2640362E (pt)	2010-11-19	2014-11-28	Gilead Sciences Inc	Composições terapêuticas compreendendo hcl de rilpivirina e tenofovir disoproxil fumarato
WO2012125993A1 (en)	2011-03-17	2012-09-20	Teva Pharmaceutical Industries Ltd.	Solid state forms of rilpivirine base, and rilipivirine salts
CA2834257C (en)	2011-04-25	2019-03-12	Hetero Research Foundation	Process for rilpivirine
EA027451B1 (ru)	2011-08-30	2017-07-31	Схди Фаундейшн, Инк.	Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и их применение
CA2848631C (en)	2011-09-16	2019-10-01	Hetero Research Foundation	Rilpivirine hydrochloride
WO2013063401A1 (en)	2011-10-28	2013-05-02	Celgene Avilomics Research, Inc.	Methods of treating a bruton's tyrosine kinase disease or disorder
EP2628732A1 (en)	2012-02-20	2013-08-21	Sandoz AG	Novel crystalline form of rilpivirine hydrochloride
EP2604593A1 (en)	2011-12-14	2013-06-19	Sandoz AG	Polymorph of Rilpivirine hydrochloride and its use as antiviral
WO2013087794A1 (en)	2011-12-14	2013-06-20	Sandoz Ag	Polymorph of rilpivirine hydrochloride and its use as antiviral
WO2013138502A1 (en)	2012-03-15	2013-09-19	Celgene Avilomics Research, Inc.	Salts of an epidermal growth factor receptor kinase inhibitor
JP6317319B2 (ja)	2012-03-15	2018-04-25	セルジーンシーエーアールエルエルシー	上皮成長因子受容体キナーゼ阻害剤の固体形態
WO2013153162A1 (en)	2012-04-11	2013-10-17	Sandoz Ag	Polymorph of rilpivirine hydrochloride
WO2013153161A2 (en)	2012-04-11	2013-10-17	Sandoz Ag	Novel polymorph of rilpivirine hydrochloride
WO2013179105A1 (en) *	2012-06-01	2013-12-05	Laurus Labs Private Limited	Improved process for preparation of rilpivirine and pharmaceutically acceptable salts thereof
ES2664094T3 (es) *	2012-07-12	2018-04-18	Hetero Research Foundation	Procedimiento de preparación de rilpivirina utilizando un intermedio nuevo
WO2014072419A1 (en)	2012-11-08	2014-05-15	Universiteit Antwerpen	Novel anti-hiv compounds
EP2935226A4 (en)	2012-12-21	2016-11-02	Celgene Avilomics Res Inc	HETEROARYL COMPOUNDS AND USES THEREOF
US9561228B2 (en)	2013-02-08	2017-02-07	Celgene Avilomics Research, Inc.	ERK inhibitors and uses thereof
US9914709B2 (en)	2013-06-21	2018-03-13	Yale University	Compositions and methods of treating HIV-1 infections using same
US9492471B2 (en)	2013-08-27	2016-11-15	Celgene Avilomics Research, Inc.	Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
US9415049B2 (en)	2013-12-20	2016-08-16	Celgene Avilomics Research, Inc.	Heteroaryl compounds and uses thereof
US10258621B2 (en) *	2014-07-17	2019-04-16	Chdi Foundation, Inc.	Methods and compositions for treating HIV-related disorders
ES2741785T3 (es)	2014-08-13	2020-02-12	Celgene Car Llc	Formas y composiciones de un inhibidor de ERK
BR112017006005A2 (pt)	2014-09-26	2017-12-19	Glaxosmithkline Ip No 2 Ltd	composição farmacêutica, e, método de prevenção ou tratamento de uma infecção por hiv.
CZ201532A3 (cs)	2015-01-21	2015-02-25	Zentiva, K.S.	Způsob výroby vysoce čistého Rilpivirinu a jeho solí
CN104926829A (zh) *	2015-06-08	2015-09-23	山东大学	一种噻吩并嘧啶类衍生物及其制备方法和应用
PL3607939T3 (pl)	2015-06-30	2022-11-07	Gilead Sciences, Inc.	Formulacje farmaceutyczne zawierające tenofowir i emtrycytabinę
CZ2015579A3 (cs)	2015-08-27	2017-03-08	Zentiva, K.S.	Krystalická forma A Rilpivirin Adipátu a způsob její přípravy
CN106187916B (zh) *	2016-07-04	2018-08-21	宜昌人福药业有限责任公司	一种有效去除利匹韦林异构体的方法
MA46563B1 (fr)	2016-10-24	2024-01-31	Janssen Sciences Ireland Unlimited Co	Compositions dispersibles
CN106749203B (zh) *	2016-11-28	2020-04-10	洛阳聚慧医药科技有限公司	一种嘧啶类杂环化合物、嘧啶类杂环化合物盐以及制备方法和应用
CN106588696B (zh) *	2016-12-08	2018-12-25	西北师范大学	一种反式α,β-不饱和腈类化合物的制备方法
CN106905244B (zh) *	2017-02-27	2019-08-16	武汉工程大学	二芳基嘧啶-二酮酸类杂合型hiv-1抑制剂及其制备方法
EP3645003A4 (en)	2017-06-30	2021-03-10	VIIV Healthcare Company	COMBINATION AND USES AND TREATMENTS THEREOF
MX2021003158A (es)	2018-09-18	2021-07-16	Nikang Therapeutics Inc	Derivados de anillo tricíclico condensado como inhibidores de la fosfatasa de homología a src 2.
CN109293581B (zh) *	2018-09-21	2020-03-27	宜昌人福药业有限责任公司	一种制备盐酸利匹韦林异构体z和杂质x的方法及杂质x作为杀虫剂在农业中的应用
EP3870568B1 (en)	2018-10-25	2023-06-28	Minakem	Process for the preparation of rilpivirine
CN114126655A (zh) *	2019-07-03	2022-03-01	爱尔兰詹森科学公司	用利匹韦林治疗儿科患者的hiv的方法
CN110526873B (zh) *	2019-08-15	2022-09-16	复旦大学	氰乙烯基取代的苯并二芳基嘧啶类化合物及其制备方法和用途
US11166952B2 (en)	2019-11-29	2021-11-09	Aptorum Therapeutics Limited	Composition including rilpivirine and method for treating tumors or cancer
CN111004215B (zh) *	2019-12-22	2022-08-09	华北理工大学	2,4-取代嘧啶类衍生物及其制备方法和在制备抗肿瘤药物中的应用
CN111217833B (zh) *	2020-02-21	2021-03-16	山东大学	噻吩并[2,3-d]嘧啶类HIV-1非核苷类逆转录酶抑制剂及其制备方法和应用
AU2021302678A1 (en) *	2020-06-30	2023-02-09	University Of South Australia	New therapeutic use of Rilpivirine
CN112028836B (zh) *	2020-09-09	2021-12-07	山东大学	一种含有六元氮杂环的二芳基嘧啶类衍生物及其制备方法与应用
CN112010810B (zh) *	2020-09-09	2024-01-30	瑞阳制药股份有限公司	一锅法制备高纯度利匹韦林中间体的方法
WO2022079739A1 (en)	2020-10-14	2022-04-21	Cipla Limited	Fixed dose compositions of cabotegravir and rilpivirine
UY39520A (es)	2020-11-17	2022-05-31	Janssen Sciences Ireland Unlimited Co	Tratamiento o prevención de la infección por vih
CN112546969B (zh) *	2020-12-07	2022-12-23	安徽贝克制药股份有限公司	催化加氢连续生产装置和利托那韦中间体的制备方法
CN112778214A (zh) *	2021-01-13	2021-05-11	安徽贝克联合制药有限公司	用于合成利匹韦林的中间体、其合成方法和利匹韦林的合成方法
CN113105394A (zh) *	2021-03-08	2021-07-13	复旦大学	一种含芳杂环结构的联苯二芳基嘧啶类衍生物及其制备方法和应用
CN113461666A (zh) *	2021-05-06	2021-10-01	复旦大学	含芳杂环结构的联苯二芳基甲基嘧啶衍生物及其制备方法
CN113845515A (zh) *	2021-09-03	2021-12-28	复旦大学	一种含芳杂环结构的二甲基联苯二芳基嘧啶类衍生物及其制备方法和应用
WO2023088964A1 (en)	2021-11-17	2023-05-25	Janssen Sciences Ireland Unlimited Company	Dissolution test
EP4511007A1 (en)	2022-04-22	2025-02-26	Janssen Sciences Ireland Unlimited Company	Freeze dried compositions
EP4511003A1 (en)	2022-04-22	2025-02-26	Janssen Sciences Ireland Unlimited Company	Liquid compositions
TW202408526A (zh)	2022-05-17	2024-03-01	愛爾蘭商健生科學愛爾蘭無限公司	治療或預防hiv感染(一)
WO2023222755A1 (en)	2022-05-17	2023-11-23	Janssen Sciences Ireland Unlimited Company	Treatment or prevention of hiv infection
CN115490642B (zh) *	2022-09-21	2024-11-15	山东大学	一种含醚键的二芳基嘧啶类化合物及其制备方法与应用

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3459731A (en)	1966-12-16	1969-08-05	Corn Products Co	Cyclodextrin polyethers and their production
US3953398A (en) *	1970-07-20	1976-04-27	The Goodyear Tire & Rubber Company	Age resistant polymeric compositions
JPS63159316A (ja) *	1977-11-28	1988-07-02	アルキユサル　インコーポレーテツド　ピーテイワイ　リミテツド	中性銅結合体を含む抗炎症組成物
EP0002341B1 (en) *	1977-11-28	1982-01-20	Barry Boettcher	Complexes of bivalent copper, methods of preparation thereof and compositions containing said complexes
JPS5879920A (ja) *	1981-11-09	1983-05-13	Kanegafuchi Chem Ind Co Ltd	血小板凝集阻害剤
GB9012592D0 (en)	1990-06-06	1990-07-25	Smithkline Beecham Intercredit	Compounds
US5318780A (en) *	1991-10-30	1994-06-07	Mediventures Inc.	Medical uses of in situ formed gels
US5691364A (en)	1995-03-10	1997-11-25	Berlex Laboratories, Inc.	Benzamidine derivatives and their use as anti-coagulants
GB9523675D0 (en) *	1995-11-20	1996-01-24	Celltech Therapeutics Ltd	Chemical compounds
PL189122B1 (pl)	1995-11-23	2005-06-30	Janssen Pharmaceutica Nv	Sposób wytwarzania mieszaniny stałej zawierającejjedną lub wiele cyklodekstryn, mieszanina stała ikompozycja farmaceutyczna
TW429256B (en)	1995-12-27	2001-04-11	Janssen Pharmaceutica Nv	1-(1,2-disubstituted piperidinyl)-4-(benzimidazolyl- and imidazopyridinyl)-piperidine derivatives
GB9705361D0 (en)	1997-03-14	1997-04-30	Celltech Therapeutics Ltd	Chemical compounds
JP3990808B2 (ja) *	1998-03-26	2007-10-17	Ｔｄｋ株式会社	非水電解質電池用電極の製造方法
DE69943247D1 (de) *	1998-03-27	2011-04-14	Janssen Pharmaceutica Nv	HIV hemmende Pyrimidin Derivate
EP0945447A1 (en) *	1998-03-27	1999-09-29	Janssen Pharmaceutica N.V.	Trisubstituted 1,3,5-triazine derivatives for treatment of HIV infections
SI0945443T1 (en) *	1998-03-27	2003-08-31	Janssen Pharmaceutica N.V.	HIV inhibiting pyrimidine derivatives
JP2000035628A (ja) *	1998-07-16	2000-02-02	Konica Corp	ハロゲン化銀写真感光材料
EP1107957B1 (en) *	1998-08-29	2006-10-18	AstraZeneca AB	Pyrimidine compounds
IL143023A0 (en)	1998-11-10	2002-04-21	Janssen Pharmaceutica Nv	Hiv replication inhibiting pyrimidines
WO2000053610A2 (en)	1999-03-09	2000-09-14	Pharmacia & Upjohn Company	4-OXO-4,7-DIHYDRO-THIENO[2,3-b]PYRIDINE-5-CARBOXAMIDES AS ANTIVIRAL AGENTS
IL144910A0 (en)	1999-04-15	2002-06-30	Bristol Myers Squibb Co	Cyclic compounds and pharmaceutical compositions containing the same
GB9914258D0 (en)	1999-06-18	1999-08-18	Celltech Therapeutics Ltd	Chemical compounds
DE19945982A1 (de)	1999-09-24	2001-03-29	Knoll Ag	Geschwindigkeitsbestimmte Partikel
PL207590B1 (pl) *	1999-09-24	2011-01-31	Janssen Pharmaceutica Nv	Cząstka stanowiąca dyspersję stałą oraz postać dawkowania, sposób ich otrzymywania i zastosowanie
KR20030024659A (ko) *	2000-02-17	2003-03-26	암겐 인코포레이티드	키나제 억제제
GB0004888D0 (en)	2000-03-01	2000-04-19	Astrazeneca Uk Ltd	Chemical compounds
GB0004887D0 (en) *	2000-03-01	2000-04-19	Astrazeneca Uk Ltd	Chemical compounds
ES2542326T3 (es)	2000-05-08	2015-08-04	Janssen Pharmaceutica Nv	Inhibidores de la replicación del VIH
CA2407754C (en)	2000-05-08	2009-09-15	Janssen Pharmaceutica N.V.	Prodrugs of hiv replication inhibiting pyrimidines
US6596729B2 (en) *	2000-07-20	2003-07-22	Bristol-Myers Squibb Company	Tricyclic-2-pyridone compounds useful as HIV reverse transcriptase inhibitors
CZ20032366A3 (en)	2001-03-02	2004-04-14	Smithkline Beecham Corporation	Benzophenones as inhibitors of reverse transcriptase
EP1373257B9 (en) *	2001-03-29	2008-10-15	Vertex Pharmaceuticals Incorporated	Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
US8101629B2 (en) *	2001-08-13	2012-01-24	Janssen Pharmaceutica N.V.	Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
US7638522B2 (en)	2001-08-13	2009-12-29	Janssen Pharmaceutica N.V.	Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
JO3429B1 (ar)	2001-08-13	2019-10-20	Janssen Pharmaceutica Nv	مشتقات برميدينات مثبطة فيروس الايدز
MY169670A (en)	2003-09-03	2019-05-08	Tibotec Pharm Ltd	Combinations of a pyrimidine containing nnrti with rt inhibitors
CA2457526A1 (en) *	2001-08-29	2003-03-13	Umd, Inc.	Vaginal delivery of chemotherapeutic agents and inhibitors of membrane efflux systems for cancer therapy
TWI329105B (en) *	2002-02-01	2010-08-21	Rigel Pharmaceuticals Inc	2,4-pyrimidinediamine compounds and their uses
EP1504047B1 (en) *	2002-05-03	2007-12-12	Janssen Pharmaceutica N.V.	Polymeric microemulsions
CA2493794C (en)	2002-08-09	2010-05-25	Janssen Pharmaceutica N.V.	Processes for the preparation of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
WO2004050068A1 (en)	2002-11-29	2004-06-17	Janssen Pharmaceutica N.V.	Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
CL2004000192A1 (es)	2003-02-07	2005-03-18	Janssen Pharmaceutica Nv	Uso de compuestos derivados de 2-aminopirimidina para preparar un medicamento para la prevencion de una infeccion por vih relaciones sexuales o un contacto intimo en la pareja.
WO2011103559A1 (en) *	2010-02-22	2011-08-25	Nektar Therapeutics	Oligomer modified diaromatic substituted compounds

2002
- 2002-07-16 JO JOP/2002/0074A patent/JO3429B1/ar active
- 2002-08-09 DK DK02764839.3T patent/DK1419152T3/da active
- 2002-08-09 SI SI200230963T patent/SI1419152T1/sl unknown
- 2002-08-09 MY MYPI20071005A patent/MY189572A/en unknown
- 2002-08-09 PL PL368270A patent/PL216398B1/pl unknown
- 2002-08-09 LT LTEP20165399.5T patent/LT3808743T/lt unknown
- 2002-08-09 CN CNB028159209A patent/CN100509801C/zh not_active Expired - Lifetime
- 2002-08-09 AP APAP/P/2004/002993A patent/AP1610A/en active
- 2002-08-09 DK DK20165399.5T patent/DK3808743T3/da active
- 2002-08-09 MX MXPA04001401A patent/MXPA04001401A/es active IP Right Grant
- 2002-08-09 ES ES10178189T patent/ES2799408T3/es not_active Expired - Lifetime
- 2002-08-09 PT PT02764839T patent/PT1419152E/pt unknown
- 2002-08-09 KR KR1020047000372A patent/KR100817453B1/ko not_active Expired - Lifetime
- 2002-08-09 EA EA200400304A patent/EA006656B1/ru active IP Right Maintenance
- 2002-08-09 OA OA1200400047A patent/OA12652A/en unknown
- 2002-08-09 BR BR122015023612A patent/BR122015023612B8/pt not_active IP Right Cessation
- 2002-08-09 WO PCT/EP2002/008953 patent/WO2003016306A1/en active Application Filing
- 2002-08-09 HU HU1900370A patent/HU231274B1/hu active Protection Beyond IP Right Term
- 2002-08-09 BR BRPI0211909-9 patent/BRPI0211909B8/pt active IP Right Grant
- 2002-08-09 IL IL16032802A patent/IL160328A0/xx active IP Right Grant
- 2002-08-09 CA CA002452217A patent/CA2452217C/en not_active Expired - Lifetime
- 2002-08-09 SI SI200231101T patent/SI3808743T1/sl unknown
- 2002-08-09 PL PL402388A patent/PL402388A1/pl unknown
- 2002-08-09 CN CN200910145401.5A patent/CN101816658B/zh not_active Expired - Lifetime
- 2002-08-09 US US10/485,636 patent/US7125879B2/en active Active
- 2002-08-09 ES ES20165399T patent/ES2923581T3/es not_active Expired - Lifetime
- 2002-08-09 NZ NZ530951A patent/NZ530951A/en not_active IP Right Cessation
- 2002-08-09 ES ES02764839T patent/ES2368996T3/es not_active Expired - Lifetime
- 2002-08-09 HU HU0401346A patent/HU230192B1/hu active Protection Beyond IP Right Term
- 2002-08-09 BR BR122015032641-9A patent/BR122015032641B1/pt not_active IP Right Cessation
- 2002-08-09 EP EP20165399.5A patent/EP3808743B1/en not_active Expired - Lifetime
- 2002-08-09 EP EP10178189.6A patent/EP2298761B1/en not_active Expired - Lifetime
- 2002-08-09 AT AT02764839T patent/ATE517891T1/de active
- 2002-08-09 JP JP2003521229A patent/JP2005507380A/ja not_active Withdrawn
- 2002-08-09 KR KR1020077022611A patent/KR100969273B1/ko not_active Expired - Lifetime
- 2002-08-09 EP EP02764839A patent/EP1419152B1/en not_active Expired - Lifetime
- 2002-08-09 HR HRP20192051AA patent/HRP20192051B1/hr not_active IP Right Cessation
- 2002-08-09 AU AU2002329238A patent/AU2002329238C1/en active Active
- 2002-08-10 EG EG2002080892A patent/EG24684A/xx active
- 2002-08-12 AR ARP020103034A patent/AR036387A1/es active IP Right Grant
- 2002-08-12 PA PA20028552901A patent/PA8552901A1/es unknown
- 2002-09-08 UA UA2004031903A patent/UA78221C2/uk unknown
2004
- 2004-01-29 HR HRP20040096AA patent/HRP20040096B1/hr not_active IP Right Cessation
- 2004-02-11 IL IL160328A patent/IL160328A/en active Protection Beyond IP Right Term
- 2004-02-12 ZA ZA2004/01159A patent/ZA200401159B/en unknown
- 2004-02-12 NO NO20040633A patent/NO327639B1/no not_active IP Right Cessation
2005
- 2005-04-01 HK HK05102760.9A patent/HK1070066A1/xx not_active IP Right Cessation
2006
- 2006-06-26 US US11/474,855 patent/US8080551B2/en not_active Expired - Fee Related
2008
- 2008-09-02 NO NO20083770A patent/NO337142B1/no not_active IP Right Cessation
2009
- 2009-11-12 JP JP2009259107A patent/JP5247661B2/ja not_active Expired - Lifetime
2010
- 2010-12-21 HK HK10111939.9A patent/HK1145449A1/xx not_active IP Right Cessation
2011
- 2011-06-16 JP JP2011134088A patent/JP4838396B2/ja not_active Expired - Lifetime
- 2011-06-17 JP JP2011135468A patent/JP5539927B2/ja not_active Expired - Lifetime
- 2011-09-30 US US13/249,796 patent/US20120076835A1/en not_active Abandoned
- 2011-10-26 CY CY20111101014T patent/CY1112331T1/el unknown
2012
- 2012-03-23 HR HRP20120265A patent/HRP20120265B1/hr not_active IP Right Cessation
- 2012-05-08 BE BE2012C020C patent/BE2012C020I2/nl unknown
- 2012-05-16 LU LU92001C patent/LU92001I2/fr unknown
- 2012-05-18 CY CY2012012C patent/CY2012012I2/el unknown
- 2012-05-22 FR FR12C0035C patent/FR12C0035I2/fr active Active
- 2012-05-23 NO NO2012010C patent/NO2012010I2/no unknown
- 2012-05-24 BE BE2012C022C patent/BE2012C022I2/nl unknown
- 2012-05-24 LU LU92008C patent/LU92008I2/fr unknown
- 2012-05-25 FR FR12C0036C patent/FR12C0036I2/fr active Active
- 2012-05-25 CY CY2012013C patent/CY2012013I1/el unknown
- 2012-05-25 DE DE201212000038 patent/DE122012000038I1/de active Pending
2014
- 2014-08-05 US US14/451,761 patent/US9580392B2/en not_active Expired - Fee Related
2015
- 2015-10-20 HU HUS1500051C patent/HUS1500051I1/hu unknown
2016
- 2016-02-03 HU HUS1500055C patent/HUS1500055I1/hu unknown
2017
- 2017-01-16 US US15/406,918 patent/US20170121292A1/en not_active Abandoned
- 2017-07-20 US US15/655,570 patent/US9981919B2/en not_active Expired - Lifetime
2018
- 2018-04-26 US US15/963,352 patent/US10370340B2/en not_active Expired - Fee Related
2019
- 2019-07-02 US US16/460,898 patent/US10611732B2/en not_active Expired - Fee Related
2022
- 2022-07-27 FR FR22C1036C patent/FR22C1036I1/fr active Active
- 2022-07-28 BE BE2022C531C patent/BE2022C531I2/nl unknown
- 2022-08-01 CY CY2022024C patent/CY2022024I2/el unknown
- 2022-08-02 HU HUS2200038C patent/HUS2200038I1/hu unknown
- 2022-08-02 LT LTPA2022515C patent/LTC3808743I2/lt unknown

Also Published As

Publication number	Publication date
US20060252764A1 (en)	2006-11-09
BE2012C020I2 (da)	2021-07-19
US7125879B2 (en)	2006-10-24
IL160328A (en)	2011-01-31
EP2298761A1 (en)	2011-03-23
HU230192B1 (hu)	2015-09-28
HUS1500051I1 (hu)	2018-05-28
EP3808743B1 (en)	2022-07-20
HUS1500055I1 (hu)	2016-03-29
US20190322628A1 (en)	2019-10-24
HUP0401346A3 (en)	2009-03-02
PT1419152E (pt)	2011-10-11
PL216398B1 (pl)	2014-03-31
PL368270A1 (en)	2005-03-21
BR122015032641B1 (pt)	2022-03-03
CY2022024I1 (el)	2023-01-05
ES2368996T3 (es)	2011-11-24
WO2003016306A1 (en)	2003-02-27
UA78221C2 (uk)	2007-03-15
US20170121292A1 (en)	2017-05-04
JP2005507380A (ja)	2005-03-17
JP5539927B2 (ja)	2014-07-02
IL160328A0 (en)	2004-07-25
US20040198739A1 (en)	2004-10-07
US8080551B2 (en)	2011-12-20
AU2002329238C1 (en)	2008-08-28
LTC3808743I2 (da)	2023-04-25
ES2799408T3 (es)	2020-12-17
KR100969273B1 (ko)	2010-08-20
HUS2200038I1 (hu)	2022-08-28
KR20070101409A (ko)	2007-10-16
NO337142B1 (no)	2016-02-01
US20180244632A1 (en)	2018-08-30
CY1112331T1 (el)	2015-08-05
JP2011225589A (ja)	2011-11-10
US9981919B2 (en)	2018-05-29
FR22C1036I1 (fr)	2022-09-09
CN1541215A (zh)	2004-10-27
EA200400304A1 (ru)	2004-08-26
JO3429B1 (ar)	2019-10-20
DE122012000038I1 (de)	2012-09-20
HRP20040096A2 (en)	2004-06-30
HRP20120265A2 (hr)	2012-05-31
US20120076835A1 (en)	2012-03-29
FR12C0035I1 (da)	2012-06-22
MXPA04001401A (es)	2004-05-27
US10611732B2 (en)	2020-04-07
BR122015023612B8 (pt)	2021-05-25
CY2012012I1 (el)	2015-08-05
NO2012010I1 (no)	2012-06-18
US20140343006A1 (en)	2014-11-20
EA006656B1 (ru)	2006-02-24
AU2002329238B2 (en)	2008-01-24
ATE517891T1 (de)	2011-08-15
HK1070066A1 (en)	2005-06-10
BR0211909A (pt)	2004-08-24
CY2012013I2 (el)	2015-08-05
CY2012013I1 (el)	2015-08-05
CY2012012I2 (el)	2015-08-05
HRP20192051A2 (hr)	2020-03-06
HU231274B1 (hu)	2022-07-28
EP2298761B1 (en)	2020-03-25
LU92008I2 (fr)	2012-07-24
KR100817453B1 (ko)	2008-03-27
NO327639B1 (no)	2009-09-07
EP3808743A1 (en)	2021-04-21
HRP20040096B1 (hr)	2013-06-30
CY2022024I2 (el)	2023-01-05
CN100509801C (zh)	2009-07-08
PA8552901A1 (es)	2003-02-28
MY189572A (en)	2022-02-17
AP2004002993A0 (en)	2004-03-31
JP2011236221A (ja)	2011-11-24
AP1610A (en)	2006-05-08
HRP20192051B1 (hr)	2022-05-27
FR12C0036I1 (da)	2012-06-29
ZA200401159B (en)	2005-07-27
DK3808743T3 (da)	2022-08-01
SI1419152T1 (sl)	2011-11-30
HRP20120265B1 (hr)	2019-11-29
DK1419152T3 (da)	2011-10-24
KR20040023645A (ko)	2004-03-18
FR12C0035I2 (fr)	2016-02-12
US10370340B2 (en)	2019-08-06
BE2012C022I2 (da)	2022-01-12
HUP0401346A2 (hu)	2004-12-28
NO20040633L (no)	2004-03-12
FR12C0036I2 (fr)	2016-05-06
EP1419152B1 (en)	2011-07-27
NO2012010I2 (no)	2013-09-02
ES2923581T3 (es)	2022-09-28
BRPI0211909B1 (pt)	2018-05-29
LTPA2022515I1 (da)	2022-08-25
EP1419152A1 (en)	2004-05-19
HK1145449A1 (en)	2011-04-21
OA12652A (en)	2006-06-15
JP4838396B2 (ja)	2011-12-14
SI3808743T1 (sl)	2022-09-30
LU92001I2 (fr)	2012-07-16
CN101816658B (zh)	2014-08-27
EG24684A (en)	2010-05-05
CA2452217C (en)	2009-06-16
CA2452217A1 (en)	2003-02-27
AR036387A1 (es)	2004-09-08
NZ530951A (en)	2005-10-28
US20170320835A1 (en)	2017-11-09
BR122015023612B1 (pt)	2021-01-19
PL402388A1 (pl)	2013-04-02
BRPI0211909B8 (pt)	2021-05-25
LT3808743T (lt)	2022-08-10
NO20083770L (no)	2004-03-12
CN101816658A (zh)	2010-09-01
JP2010077140A (ja)	2010-04-08
JP5247661B2 (ja)	2013-07-24
US9580392B2 (en)	2017-02-28

Publication	Publication Date	Title
LTPA2022515I1 (da)	2022-08-25
BE2014C052I2 (da)	2022-02-01
BE2014C036I2 (da)	2021-11-22
BE2014C004I2 (da)	2021-11-22
BE2012C050I2 (da)	2021-03-23
BE2011C034I2 (da)	2021-11-22
BE2007C047I2 (da)	2021-06-04
AU2002307149A8 (da)	2002-10-21
JP2002199153A5 (da)	2008-09-18
JP2002078724A5 (da)	2008-12-04
JP2001309299A5 (da)	2008-04-24
BRPI0209186B1 (da)	2012-11-13
JP2002141589A5 (da)	2009-03-26
IN2002KO00075A (da)	2006-11-24
BRPI0204884B1 (da)	2011-05-17
CH1379220H1 (da)	2018-10-31
JP2002073554A5 (da)	2008-06-26
JP2002204493A5 (da)	2005-06-30
BRPI0101486B8 (da)	2021-05-25
BE2012C051I2 (da)	2022-02-02
BRPI0210463A2 (da)	2017-07-11
JP2002235575A5 (da)	2005-06-16
JP2002234202A5 (da)	2006-02-02
AU2000280389A8 (da)	2003-07-24
JP2002091087A5 (da)	2008-08-28